SAR and potential of the aureobasidin class of antifungal agents

Current Opinion in Anti-infective Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 375-386

  Kurome, T ^a   Takesako, K ^a  

^a TAKARA SHUZO CO LTD   (Japan)

Author keywords

Antifungal; Aureobasidin; Cyclic peptolide; Inositol phosphorylceramide (IPC) synthase; SAR

Indexed keywords

ANTIFUNGAL AGENT; AUREOBASIDIN; CYCLODEPSIPEPTIDE; SYNTHETASE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; ASPERGILLUS FUMIGATUS; AUREOBASIDIUM PULLULANS; BLASTOMYCES DERMATITIDIS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; DRUG ISOLATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HISTOPLASMA CAPSULATUM; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0033859599     PISSN: 14648458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation and properties
2. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic
3. Fungicidal action of aureobasidin A, a cyclic depsipeptide antifungal antibiotic, against Saccharomyces cerevisiae
4. AUR1, a novel gene conferring aureobasidin resistance on Saccharomyces cerevisiae: A study of defective morphologies in Aur1p-depleted cells
5. The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY-295337)
6. Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene
7. Sphingolipid functions in Saccharomyces cerevisiae: Comparison to mammals
8. Structure of aureobasidin A.
9. NMR studies of aureobasidins A and E
10. Structures of aureobasidins B to R
11. Isolation, structures, and antifungal activities of new aureobasidins
12. Structures and antifungal activities of new aureobasidins
13. Conformational feature of aureobasidin E, a new type of potent antifungal antibiotic
14. X-ray and NMR conformational study of aureobasidin E: A cyclic depsipeptide with potent antifungal activity
15. Unique molecular conformation of aureobasidin A, a highly amide N-methylated cyclic depsipeptide with potent antifungal activity: X-ray crystal structure and molecular modeling studies
16. Precursor directed biosynthesis of aureobasidins
17. Total synthesis of aureobasidin A, an antifungal cyclic depsipeptide
18. Total synthesis of antifungal cyclic depsipeptide aureobasidin A
19. Total synthesis of the antifungal cyclic depsipeptides Sch-57967 and aureobasidin A
20. Contribution to the synthesis of aureobasidin A. Synthesis of cyclopeptolides containing the sequence leucyl-N-methyl-β-hydroxyvalyl-(2R)-oxy-(3R)-methyl-pentanoic acid
21. Aldol-promoted reaction of R106-sarcosine: Synthesis and conformational analysis of novel R106 analogs
22. Trimethylamine N-oxide: A novel reagent for the promotion of the retro-aldol reaction of R106-1 (LY-295337)
23. Structure-activity relationship of antifungal aureobasidin A, inhibitor of sphingolipid biosynthesis: Synthesis of new active aureobasidin against Aspergillus fumigatus
24. Oxybenzotriazole free peptide coupling reagents for N-methylated amino acids
25. Reactifs de coupling peptidique IV (1) L7 hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (BOP)
26. Solid-phase synthesis of cyclosporin peptides
27. Site-specific ring opening of depsipeptide aureobasidin A in hydrogen fluoride
28. Conformationally restricted bicyclic analogs of somatostatin
29. Conformation of the LL and LD hairpin bends with internal hydrogen bonds in proteins and peptides
30. Syntheses of antifungal aureobasidin A analogs with alkyl chains for structure-activity relationship
31. Relationship between structure and biological activity of novel R106 analogs
32. Lipopeptide antifungal agents
33. LY295337, a novel depsipeptide antifungal antibiotic. II. In vivo antifungal activity
34. LY295337, a novel depsipeptide antifungal antibiotic. III. Resistance development studies
35. Efficacy of LY295337 (LY) in a rat model of pulmonary aspergillos (PA) and cryptococcal meningitis (CM)
36. Inhibition of yeast inositol phosphorylceramide synthase by aureobasidin A measured by a fluorometric assay
37. Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species
38. Isolation and characterization of the aureobasidin A-resistant gene on Schizosaccharomyces pombe: Roles of Aur1p+ in cell morphogenesis
39. An aureobasidin A resistance gene isolated from Aspergillus is a homolog of yeast AUR1, a gene responsible for inositol phosphorylceramide (IPC) synthase activity
40. Inositol phosphoryl transferases from human pathogenic fungi
41. Kharefungin, a novel inhibitor of sphingolipid synthesis
42. Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase
43. Cryptococcus neoformans from host animals exhibits decreased susceptibility to aureobasidin A (R106-I, LY295337)
44. Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins
45. Role of ABC transporters in aureobasidin A resistance
46. Aureobasidins as new inhibitors of P-glycoprotein in multidrug resistant tumor cells
47. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
48. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
49. Aureobasidins: Structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter